Cancer types
  • Lymphomas
Title of study
Prediction tools for Hodgkin lymphoma patients to weigh benefits and harms of different treatment and survivorship care strategies.
Version Number
Approval Date 
1, 6 November 2020
Short Title
Study site
Principle Investigator
Prof. dr. ir. F.E. van Leeuwen
Investigator Maastro
Drs. B.D.P. Ta
Nederlands Kanker Instituut/ Antoni van Leeuwenhoek (NKI-AVL)
Trial registry

This study aims to develop prediction tools for risks of late adverse effects for patients with Hodgkin lymphoma (HL), both new patients and survivors, and to develop a decision support tool for new patients to weigh the benefits and harms of specific treatments. Ultimately, the purpose is to facilitate personalized decision making regarding the optimal treatment and thereby improve patient outcomes.
– To predict, for different HL treatment strategies, the absolute risks of various SMNs, CVDs and infertility for individual HL patients over a specified time interval (up to 30 years post-treatment), taking into account age and other established risk factors;
– To predict, for different HL treatment strategies, the absolute risks of HL recurrence (and mortality) up to 10 years after diagnosis, accounting for patient and disease characteristics;
– To develop a user-friendly comprehensive online HL-Treatment Decision Support Tool for newly diagnosed HL patients, enabling comparison of the benefits (cure) and harms (adverse events) of various treatments, as modeled in the first two objectives;
– To develop an online HL-Survivorship Care Management Support Tool to support better tailored surveillance/interventions for survivors at high risk of late treatment effects;
– To determine whether HL patients and clinicians are satisfied with the usability and information content of our newly-developed prediction tools.

Primary Endpoint 
Secondary Endpoints